1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. SoftOx Solutions AS
  6. News
  7. Summary
    SOFTX   NO0010811961

SOFTOX SOLUTIONS AS

(SOFTX)
Real-time Oslo Bors  -  05/20 10:19:32 am EDT
42.00 NOK   -2.33%
05/19SOFTOX SOLUTIONS AS : Announces positive phase 1 results for softox inhalation solution (sis)
AQ
05/18SoftOx Solutions AS Announces Positive Phase 1 Results for SoftOx Inhalation Solution
CI
05/18SOFTOX SOLUTIONS AS : to attend and host an educational symposium at the European Wound Management Association Conference
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SOFTX: Ex. Right to receive subscription rights in potential repair offering

12/16/2021 | 01:31am EDT
Issuer name: SoftOx Solutions AS
Ex. Date: 16 December 2021
Type of corporate action: potential repair offering 

This information is published in accordance with the requirements of the
Euronext Growth Oslo RB II - Issuer Rules 

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SotfOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange

All news about SOFTOX SOLUTIONS AS
05/19SOFTOX SOLUTIONS AS : Announces positive phase 1 results for softox inhalation solution (s..
AQ
05/18SoftOx Solutions AS Announces Positive Phase 1 Results for SoftOx Inhalation Solution
CI
05/18SOFTOX SOLUTIONS AS : to attend and host an educational symposium at the European Wound Ma..
AQ
05/12SOFTOX SOLUTIONS AS : Annual general meeting held
AQ
05/11SOFTOX SOLUTIONS AS : The SBE-01 phase 1 clinical study enters the final phase 1b
AQ
05/10SoftOx Solutions AS Announces the Last Patient Completes the Last Single-Dose Cohort of..
CI
05/05SOFTOX SOLUTIONS AS : Notice of Annual General Meeting
AQ
05/04SOFTOX SOLUTIONS AS : Annual Report 2021
AQ
04/28SOFTOX SOLUTIONS AS : Announces advancement into next phase (1b) in the SBE project
AQ
04/28Softox Solutions AS Announces Advancement into Next Phase (1B) in the SBE Project
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 434 M 44,5 M 44,5 M
EV / Sales -1
EV / Sales 0
Nbr of Employees 23
Free-Float 59,0%
Chart SOFTOX SOLUTIONS AS
Duration : Period :
SoftOx Solutions AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOFTOX SOLUTIONS AS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Geir Hermod Almňs Chief Executive Officer
Kristine Mundal R°d Chief Financial Officer
Melvin Teigen Chairman
Glenn Gundersen Medical Director
Magnus Mustafa Fazli Head-Science & Research
Sector and Competitors
1st jan.Capi. (M$)
SOFTOX SOLUTIONS AS-25.00%44
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612